What are the benefits of SGLT2 inhibitors in managing comorbidities of HF?
SGLT2 inhibitors are beneficial in managing comorbidities of HF, such as diabetes, hypertension, coronary artery disease, and chronic kidney disease. Treatment of patients with T2D with SGLT2 inhibitors improves glycemic control but also significantly reduces HF events in patients with established CV disease or CV risk factors (154-156). Among patients with chronic kidney disease, SGLT2 inhibitors also decrease the risk of renal disease progression in a manner additive to renin-angiotensin-aldosterone system inhibitors (145). 